NEJM publishes study evaluating the use of semaglutide to assist people with weight loss. Not “game-changing” but another positive step forward for evidenced-based treatment to help people with #Overweight or #Obesity.

Dr. Barry Dworkin

Medical Mythbusting Commentary for February 16, 2021

Reference:Last week the NEJM published a study concluding “In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.”

A follow up editorial provides some perspective.

[display_podcast]

Related posts:

  1. Treatments for weight loss do exist, work well for many, and reveal our growing understanding of how our homeostatic, motivational, and executive brain centers interact with respect to weight control.
  2. Meta-analyses of randomized controlled trials looks at efficacy of semaglutide (Ozempic) in treating people suffering with obesity
  3. Injectable type 2 diabetes drug has added benefit of assisting weight loss
  4. Diabetes drug in short supply in U.S. (but not in Canada) after celebrities, influencers touted its weight-loss benefits.